Developer docs
API playgroundTry for free, no card

Search company profiles

Societal CDMO

Full company profile

uuid00092c3

Namestring
Societal CDMO
Legal namestring
Societal CDMO Inc.
Company typeenum
Private
Founded yearint
1982
Descriptiontext

Societal CDMO Inc. is a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Gainesville, Florida, with operations across three domestic sites in Oregon, Georgia, and Florida. The company provides integrated formulation development, analytical, and manufacturing services spanning the full drug product lifecycle from preclinical formulation through commercial supply, with explicit capabilities in oral bioavailability enhancement, multiparticulates, modified release, oral solids and liquids, dry powders for inhalation, topicals, cGMP clinical manufacturing, commercial manufacturing, technology transfer, packaging, and quality and compliance.

The underlying technology centers on pharmaceutical finished product formulation science, including spray drying, particle engineering, and complex oral dosage form design, supported by preformulation studies, process design, analytical method development, and stability programs. The service architecture is presented as an integrated platform linking design, development, and manufacturing rather than discrete stand-alone modules, with quality and compliance infrastructure embedded throughout to meet cGMP and global regulatory requirements.

The business model is a project- and contract-based CDMO revenue model, monetizing formulation development, clinical manufacturing, and commercial manufacturing services for pharmaceutical clients. Pricing is not publicly disclosed. The company was founded in 1982, employs 101-250 people, and was acquired by CoreRx, Inc. in April 2024 for $130 million, after which it has operated as a subsidiary within CoreRx's CDMO platform, currently doing business as Bend Bioscience. No named customer logos are publicly disclosed in the available sources.

Short descriptiontext

Societal CDMO (operating as Bend Bioscience) is a U.S. pharmaceutical CDMO offering integrated formulation development, analytical, and cGMP manufacturing services across oral, inhalation, and topical dosage forms for pharmaceutical clients. The company operates from three U.S. sites and is a subsidiary of CoreRx, Inc.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGainesville, United States
HQ citystring
Gainesville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmaceutical CDMO services, contract drug manufacturing, formulation development, oral solid dosage, cGMP clinical manufacturing
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Societal CDMO (operating under the Bend Bioscience brand) is a pharmaceutical finished product contract development and manufacturing organization (CDMO) offering integrated services across the drug development lifecycle from early-stage design through commercial supply. The company provides formulation development for oral solids, oral liquids, multiparticulates, modified release, dry powder inhalation, and topicals, supported by preformulation, analytical and stability testing, cGMP clinical and commercial manufacturing, technology transfer, packaging, and quality and regulatory compliance services.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bend Bioscience operates as a pharmaceutical finished product CDMO (Contract Development and Manufacturing Organization) offering integrated services across the drug development lifecycle from design through commercial manufacturing. The company provides a comprehensive portfolio of formulation development services including Oral Bioavailability Enhancement, Multiparticulates, Modified Release, Oral Dosage Form Design, Oral Solids, Oral Liquids, Powders for Inhalation, and Topicals. These formulation capabilities are complemented by manufacturing services (cGMP Clinical Manufacturing, Commercial Manufacturing), technology transfer, packaging, and analytical & stability testing. The service architecture follows a unified platform model where preformulation, analytical development, manufacturing, and quality compliance work together as an integrated offering rather than as separate modules.

Product and service15 records
1Oral Bioavailability Enhancement
CategoryFormulation Development
Description

Specialized formulation service focused on improving the oral bioavailability of drug compounds through advanced scientific techniques, intended for pharmaceutical sponsors developing oral drugs with poor bioavailability.

2Multiparticulates
CategoryFormulation Development
Description

Drug delivery service involving development and manufacturing of multiparticulates for controlled release and targeted delivery applications, for sponsors needing tailored multiparticulate dosage forms.

3Modified Release
CategoryFormulation Development
Description

Formulation development service for modified release dosage forms that control drug release timing and rate, for sponsors requiring extended, delayed, or otherwise modified release profiles.

4Oral Dosage Form Design (OSD)
CategoryFormulation Development
Description

Comprehensive oral solid dosage form design and development service covering tablets, capsules, and related formulations, for sponsors developing oral solid drug products.

5Oral Solids
CategoryManufacturing
Description

Manufacturing service for oral solid dosage forms including tablets and capsules for clinical and commercial production, intended for pharmaceutical sponsors needing cGMP oral solid supply.

6Oral Liquids
CategoryManufacturing
Description

Formulation and manufacturing service for oral liquid dosage forms including solutions, suspensions, and syrups, for sponsors developing oral liquid drug products.

7Powders for Inhalation
CategoryManufacturing
Description

Specialized manufacturing service for dry powder inhalation products requiring precise particle engineering and delivery systems, for sponsors developing inhaled therapies.

8Topicals
CategoryManufacturing
Description

Formulation and manufacturing service for topical drug products including creams, ointments, gels, and lotions, for sponsors developing topical pharmaceutical products.

9Preformulation & Process Design
CategoryPreformulation & Process Development
Description

Early-stage development service encompassing preformulation studies and process design to establish robust manufacturing parameters for pharmaceutical sponsors in early development.

10Analytical & Stability
CategoryAnalytical Services
Description

Comprehensive analytical testing and stability studies service to support drug development and regulatory submissions, for sponsors requiring method development and stability data packages.

11cGMP Clinical Manufacturing
CategoryManufacturing
Description

Clinical trial material manufacturing service compliant with current Good Manufacturing Practice regulations for early-phase clinical supplies, intended for pharmaceutical sponsors running clinical trials.

12Commercial Manufacturing
CategoryManufacturing
Description

Large-scale commercial drug product manufacturing service for global market supply, intended for pharmaceutical sponsors commercializing approved drug products.

13Technology Transfer
CategoryManufacturing Support Services
Description

Service facilitating the transfer of manufacturing processes and analytical methods from client facilities to Societal CDMO manufacturing sites, for sponsors transitioning production to the CDMO.

14Packaging
CategoryManufacturing Support Services
Description

Drug product packaging service including primary and secondary packaging for clinical and commercial supplies, for pharmaceutical sponsors needing finished packaged product.

15Quality & Compliance
CategoryQuality & Regulatory Compliance
Description

Quality assurance and regulatory compliance service ensuring adherence to cGMP and global regulatory requirements, supporting pharmaceutical sponsors through quality oversight and compliance management.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

In April 2024, CoreRx, Inc. acquired Societal CDMO Inc. for $130 million to expand its formulation development and scale-up manufacturing capabilities. This acquisition strengthened CoreRx's position in the CDMO market by adding Societal CDMO's expertise in complex drug formulations and manufacturing scale-up services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct strategic acquirer/parent of Societal CDMO; provides formulation development and small-batch manufacturing services, overlapping with Societal's preformulation and clinical supply capabilities.

TypeBroad incumbent
Description

One of the largest global CDMOs offering integrated drug product development, clinical and commercial manufacturing across oral solids, sterile, and specialty formats; a key scale competitor for Societal's commercial manufacturing work.

TypeBroad incumbent
Description

Global CDMO leader offering softgel, oral solid, inhalation, and biologics services with extensive commercial-scale capacity; competes with Societal across oral solids, modified release, and inhalation niches.

TypeDirect peer
Description

European-headquartered CDMO specializing in solid oral dosage forms, including modified release and complex formulations; directly comparable to Societal's core drug product CDMO model.

TypeDirect peer
Description

Specialty CDMO with strong capabilities in particle engineering, amorphous solid dispersions, and inhalation; overlaps directly with Societal's bioavailability enhancement and inhalation offerings.

TypeDirect peer
Description

U.S. CDMO offering formulation development, analytical services, and clinical/commercial manufacturing for oral solids and sterile products; competes with Societal in early-phase drug product development.

TypeDirect peer
Description

U.S.-based CDMO focused on oral solid dose formulation, clinical supply, and small-batch commercial manufacturing; closely comparable in scale and service mix to Societal CDMO.

TypeBroad incumbent
Description

CDMO with API and finished dosage form capabilities, including oral solids; competes for early development and commercial manufacturing programs comparable to Societal's services.

TypeEmerging player
Description

Emerging specialty CDMO focused on complex injectable and poorly soluble oral formulations; overlaps with Societal in bioavailability and modified release niches.

10Particle Sciences (Lubrizol Life Science)
TypeDirect peer
Description

Specialty CDMO focused on complex drug delivery, including particulate and modified release systems, with strong bioavailability enhancement capabilities comparable to Societal's high-science offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Societal CDMO

Pharmaceutical Contract Development and Manufacturing (CDMO)societalcdmo.com

Societal CDMO (operating as Bend Bioscience) is a U.S. pharmaceutical CDMO offering integrated formulation development, analytical, and cGMP manufacturing services across oral, inhalation, and topical dosage forms for pharmaceutical clients. The company operates from three U.S. sites and is a subsidiary of CoreRx, Inc.

What Societal CDMO does

Societal CDMO Inc. is a U.S.-based pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Gainesville, Florida, with operations across three domestic sites in Oregon, Georgia, and Florida. The company provides integrated formulation development, analytical, and manufacturing services spanning the full drug product lifecycle from preclinical formulation through commercial supply, with explicit capabilities in oral bioavailability enhancement, multiparticulates, modified release, oral solids and liquids, dry powders for inhalation, topicals, cGMP clinical manufacturing, commercial manufacturing, technology transfer, packaging, and quality and compliance.

The underlying technology centers on pharmaceutical finished product formulation science, including spray drying, particle engineering, and complex oral dosage form design, supported by preformulation studies, process design, analytical method development, and stability programs. The service architecture is presented as an integrated platform linking design, development, and manufacturing rather than discrete stand-alone modules, with quality and compliance infrastructure embedded throughout to meet cGMP and global regulatory requirements.

The business model is a project- and contract-based CDMO revenue model, monetizing formulation development, clinical manufacturing, and commercial manufacturing services for pharmaceutical clients. Pricing is not publicly disclosed. The company was founded in 1982, employs 101-250 people, and was acquired by CoreRx, Inc. in April 2024 for $130 million, after which it has operated as a subsidiary within CoreRx's CDMO platform, currently doing business as Bend Bioscience. No named customer logos are publicly disclosed in the available sources.

Societal CDMO firmographics

Firmographics
Name
Societal CDMO
Legal name
Societal CDMO Inc.
Website
https://societalcdmo.com
Company type
Private
Founded year
1982
Operating status
Acquired
Headcount range
51–100 employees
Short description
Societal CDMO (operating as Bend Bioscience) is a U.S. pharmaceutical CDMO offering integrated formulation development, analytical, and cGMP manufacturing services across oral, inhalation, and topical dosage forms for pharmaceutical clients. The company operates from three U.S. sites and is a subsidiary of CoreRx, Inc.
Ownership category
akta.pro rank

Societal CDMO industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical CDMO services
  • Contract drug manufacturing
  • Formulation development
  • Oral solid dosage
  • CGMP clinical manufacturing

Where Societal CDMO is headquartered

Location

Headquarters

HQ city
Gainesville
HQ country
United States
HQ region
North America

Markets served

Societal CDMO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Societal CDMO product offering

Product offering

Core offering

Societal CDMO (operating under the Bend Bioscience brand) is a pharmaceutical finished product contract development and manufacturing organization (CDMO) offering integrated services across the drug development lifecycle from early-stage design through commercial supply. The company provides formulation development for oral solids, oral liquids, multiparticulates, modified release, dry powder inhalation, and topicals, supported by preformulation, analytical and stability testing, cGMP clinical and commercial manufacturing, technology transfer, packaging, and quality and regulatory compliance services.

Product overview

Bend Bioscience operates as a pharmaceutical finished product CDMO (Contract Development and Manufacturing Organization) offering integrated services across the drug development lifecycle from design through commercial manufacturing. The company provides a comprehensive portfolio of formulation development services including Oral Bioavailability Enhancement, Multiparticulates, Modified Release, Oral Dosage Form Design, Oral Solids, Oral Liquids, Powders for Inhalation, and Topicals. These formulation capabilities are complemented by manufacturing services (cGMP Clinical Manufacturing, Commercial Manufacturing), technology transfer, packaging, and analytical & stability testing. The service architecture follows a unified platform model where preformulation, analytical development, manufacturing, and quality compliance work together as an integrated offering rather than as separate modules.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oral Bioavailability Enhancement Specialized formulation service focused on improving the oral bioavailability of drug compounds through advanced scientific techniques, intended for pharmaceutical sponsors developing oral drugs with poor bioavailability.
  • Multiparticulates Drug delivery service involving development and manufacturing of multiparticulates for controlled release and targeted delivery applications, for sponsors needing tailored multiparticulate dosage forms.
  • Modified Release Formulation development service for modified release dosage forms that control drug release timing and rate, for sponsors requiring extended, delayed, or otherwise modified release profiles.
  • Oral Dosage Form Design (OSD) Comprehensive oral solid dosage form design and development service covering tablets, capsules, and related formulations, for sponsors developing oral solid drug products.
  • Oral Solids Manufacturing service for oral solid dosage forms including tablets and capsules for clinical and commercial production, intended for pharmaceutical sponsors needing cGMP oral solid supply.
  • Oral Liquids Formulation and manufacturing service for oral liquid dosage forms including solutions, suspensions, and syrups, for sponsors developing oral liquid drug products.
  • Powders for Inhalation Specialized manufacturing service for dry powder inhalation products requiring precise particle engineering and delivery systems, for sponsors developing inhaled therapies.
  • Topicals Formulation and manufacturing service for topical drug products including creams, ointments, gels, and lotions, for sponsors developing topical pharmaceutical products.
  • Preformulation & Process Design Early-stage development service encompassing preformulation studies and process design to establish robust manufacturing parameters for pharmaceutical sponsors in early development.
  • Analytical & Stability Comprehensive analytical testing and stability studies service to support drug development and regulatory submissions, for sponsors requiring method development and stability data packages.
  • cGMP Clinical Manufacturing Clinical trial material manufacturing service compliant with current Good Manufacturing Practice regulations for early-phase clinical supplies, intended for pharmaceutical sponsors running clinical trials.
  • Commercial Manufacturing Large-scale commercial drug product manufacturing service for global market supply, intended for pharmaceutical sponsors commercializing approved drug products.
  • Technology Transfer Service facilitating the transfer of manufacturing processes and analytical methods from client facilities to Societal CDMO manufacturing sites, for sponsors transitioning production to the CDMO.
  • Packaging Drug product packaging service including primary and secondary packaging for clinical and commercial supplies, for pharmaceutical sponsors needing finished packaged product.
  • Quality & Compliance Quality assurance and regulatory compliance service ensuring adherence to cGMP and global regulatory requirements, supporting pharmaceutical sponsors through quality oversight and compliance management.

Companies that use Societal CDMO

Customer profile

Ideal customer profiles1 record

Societal CDMO technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Societal CDMO partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CoreRx, Inc.coreStrategic or Co-development Partner · 1 April 2024In April 2024, CoreRx, Inc. acquired Societal CDMO Inc. for $130 million to expand its formulation development and scale-up manufacturing capabilities. This acquisition strengthened CoreRx's position in the CDMO market by adding Societal CDMO's expertise in complex drug formulations and manufacturing scale-up services.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Societal CDMO competitors and assessment

Company assessment

Direct peers

  • CoreRx: Direct strategic acquirer/parent of Societal CDMO; provides formulation development and small-batch manufacturing services, overlapping with Societal's preformulation and clinical supply capabilities.
  • Aenova Group: European-headquartered CDMO specializing in solid oral dosage forms, including modified release and complex formulations; directly comparable to Societal's core drug product CDMO model.
  • Hovione: Specialty CDMO with strong capabilities in particle engineering, amorphous solid dispersions, and inhalation; overlaps directly with Societal's bioavailability enhancement and inhalation offerings.
  • Alcami Corporation: U.S. CDMO offering formulation development, analytical services, and clinical/commercial manufacturing for oral solids and sterile products; competes with Societal in early-phase drug product development.
  • Metrics Contract Services: U.S.-based CDMO focused on oral solid dose formulation, clinical supply, and small-batch commercial manufacturing; closely comparable in scale and service mix to Societal CDMO.
  • Particle Sciences (Lubrizol Life Science): Specialty CDMO focused on complex drug delivery, including particulate and modified release systems, with strong bioavailability enhancement capabilities comparable to Societal's high-science offerings.

Broad incumbents

  • Patheon (PCI Pharma Services): One of the largest global CDMOs offering integrated drug product development, clinical and commercial manufacturing across oral solids, sterile, and specialty formats; a key scale competitor for Societal's commercial manufacturing work.
  • Catalent: Global CDMO leader offering softgel, oral solid, inhalation, and biologics services with extensive commercial-scale capacity; competes with Societal across oral solids, modified release, and inhalation niches.
  • Cambrex: CDMO with API and finished dosage form capabilities, including oral solids; competes for early development and commercial manufacturing programs comparable to Societal's services.

Emerging players

  • Ascendia Pharmaceuticals: Emerging specialty CDMO focused on complex injectable and poorly soluble oral formulations; overlaps with Societal in bioavailability and modified release niches.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Societal CDMO social profiles

Digital presence

Societal CDMO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Societal CDMO leadership team

Management profile

Number of profiles

Profiles1 record

Societal CDMO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Societal CDMO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Societal CDMO

What does Societal CDMO do?

Societal CDMO (operating under the Bend Bioscience brand) is a pharmaceutical finished product contract development and manufacturing organization (CDMO) offering integrated services across the drug development lifecycle from early-stage design through commercial supply. The company provides formulation development for oral solids, oral liquids, multiparticulates, modified release, dry powder inhalation, and topicals, supported by preformulation, analytical and stability testing, cGMP clinical and commercial manufacturing, technology transfer, packaging, and quality and regulatory compliance services.

Is Societal CDMO a public or private company?

Societal CDMO is a private company. It is classified as corporate owned and is currently acquired.

When was Societal CDMO founded?

Societal CDMO was founded in 1982. It employs 51 to 100 people.

Where is Societal CDMO based?

Societal CDMO is headquartered in Gainesville, United States, in the North America region.

Who are Societal CDMO's main competitors?

Direct peers on record are CoreRx, Aenova Group, Hovione, Alcami Corporation, Metrics Contract Services and Particle Sciences (Lubrizol Life Science). Broad incumbents are Patheon (PCI Pharma Services), Catalent and Cambrex. Ascendia Pharmaceuticals is listed as an emerging player.

Does Societal CDMO have an API?

No public API is recorded for Societal CDMO.

What industry is Societal CDMO in?

Societal CDMO's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireFormulation Development Outsourcing Market Report 2026The formulation development outsourcing market is forecast to grow from $32.32 billion in 2025 to $35.45 billion in 2026 at a 9.7% CAGR, reaching $53.3 billion by 2030 with a 10.7% CAGR, driven by demand for biologics, personalized medicine, and advanced formulation technologies. The industry is increasingly adopting AI-powered platforms like NVIDIA's BioNeMo Cloud and outsourcing complex drug formulations, with North America leading the global market in 2025. In April 2024, CoreRx, Inc. acquired Societal CDMO Inc. to expand its formulation development and scale-up manufacturing capabilities.GlobeNewswireTopical Drugs Contract Development and Manufacturing Organization (CDMO) Market Research Report 2026: $121 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts 2020-2035The global topical drugs CDMO market is projected to grow from $61.16 billion in 2025 to $70.96 billion in 2026, a 16% CAGR, and further to $121.22 billion by 2030. Growth is driven by pharmaceutical outsourcing, rising dermatological conditions, and cost optimization, with Asia-Pacific dominating in 2025.YahooTopical Drugs Contract Development and Manufacturing Organization (CDMO) Market Research Report 2026: $121 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts 2020-2035The global topical drugs CDMO market is projected to grow from $61.16 billion in 2025 to $70.96 billion in 2026, reaching $121.22 billion by 2030, driven by pharmaceutical outsourcing, rising dermatological conditions, and regulatory complexities. Key market activity includes CoreRx Inc.'s acquisition of Societal CDMO Inc. for $130 million in April 2024 and SOHM Inc.'s launch of a GMP-compliant topical production facility in Carlsbad in November 2023. Asia-Pacific dominated the market in 2025, though tariffs have influenced regional manufacturing costs and supply chain strategies.YahooTopical Drugs Contract Development and Manufacturing Organization (CDMO) Market Research Report 2026: $121 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts 2020-2035ResearchAndMarkets.com published a market report projecting the global topical drugs contract development and manufacturing organization (CDMO) market to grow from $61.16 billion in 2025 to $121.22 billion by 2030, representing a compound annual growth rate of 14.3%. The market expansion is driven by rising pharmaceutical outsourcing, increasing prevalence of dermatological conditions, and growing demand for complex topical formulations and transdermal drug platforms. Notable recent developments include CoreRx Inc.'s acquisition of Societal CDMO Inc. for $130 million in April 2024 and SOHM Inc.'s launch of a GMP-compliant topical production facility in Carlsbad in November 2023.GlobeNewswireSmall Molecule Innovator CDMO Research Report 2026: $93.12 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe small molecule innovator CDMO market is projected to grow from $60.7 billion in 2025 to $93.12 billion by 2030, driven by rising R&D costs, patent expirations, and increased outsourcing by biotech firms. Asia-Pacific emerged as the largest regional market by 2025, though tariff pressures are prompting investments in regional sourcing and domestic manufacturing. Strategic partnerships and acquisitions are reshaping the competitive landscape, including SST Corporation's partnership with Viwit Pharmaceuticals and CoreRx's acquisition of Societal CDMO.YahooSmall Molecule Innovator CDMO Research Report 2026: $93.12 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe small molecule innovator CDMO market is projected to grow from $60.7 billion in 2025 to $93.12 billion by 2030, driven by rising R&D costs, patent expirations, and increased outsourcing by biotech firms. Strategic partnerships and acquisitions are actively shaping market evolution, including SST Corporation's partnership with Viwit Pharmaceuticals in August 2023 and CoreRx, Inc.'s acquisition of Societal CDMO, Inc. in April 2024. Tariffs on imported materials are increasing production costs for firms in Asia-Pacific and Europe, prompting investments in regional sourcing and domestic manufacturing to enhance supply chain resilience.YahooSmall Molecule Innovator CDMO Research Report 2026: $93.12 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com has published the Small Molecule Innovator CDMO Market Report 2026, projecting the market to grow from $60.7 billion in 2025 to $93.12 billion by 2030 at a CAGR of 8.4%. Key growth drivers include rising R&D costs, patent expirations, increasing outsourcing by biotech firms, and the prevalence of chronic diseases affecting 76.4% of U.S. adults according to the CDC. Strategic transactions such as CoreRx's April 2024 acquisition of Societal CDMO and SST Corporation's August 2023 partnership with Viwit Pharmaceuticals are highlighted as examples of market consolidation and collaboration.BendbioscienceCoreRx, Societal CDMO, and Bend Bioscience Unite Under the Bend Bioscience Brand to Provide World Class CDMO OfferingCoreRx, Societal CDMO, and Bend Bioscience have announced their unification under the Bend Bioscience brand to form a comprehensive contract development and manufacturing organization (CDMO). The merged entity combines CoreRx’s formulation development expertise, Societal CDMO’s manufacturing capabilities, and Bend Bioscience’s research leadership to offer end-to-end drug development services. This strategic move aims to enhance operational efficiencies and accelerate the delivery of therapies to global markets.PharmasourceCoreRx, Societal CDMO, and Bend Bioscience Unite Under Bend Bioscience BrandCoreRx, Societal CDMO, and Bend Bioscience have officially merged under the Bend Bioscience brand to form a fully integrated contract development and manufacturing organization (CDMO). This consolidation combines CoreRx's formulation expertise, Societal CDMO's manufacturing capabilities, and Bend Bioscience's research leadership to offer end-to-end services. The move is intended to increase operational efficiencies and accelerate the commercialization of therapies for clients.Business Wire BlogQHP Capital-Backed Entities, Bend Bioscience, CoreRx, and Societal, Announce the Appointment of a New CEOQHP Capital announced Owen Murray as CEO of its combined Bend Bioscience, CoreRx, and Societal entities. Murray previously served as CEO of Aprecia Pharmaceutical and brings over 25 years of pharmaceutical industry experience. The company aims to integrate its drug product design, formulation, and manufacturing capabilities to serve global partners.